These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37627722)

  • 1. Off-Label Use of Ceftazidime/Avibactam for the Treatment of Pan-Drug-Resistant
    Mangarov I; Georgieva R; Petkova V; Nikolova I
    Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-Label Use of Ceftazidime-Avibactam in a Premature Infant With Multidrug-Resistant
    Nascimento ADS; Passaro MF; Silva PSS; Rodriguez SF; Martins MK; Oliveira SCP; Moriel P; Visacri MB
    J Pharm Pract; 2023 Aug; 36(4):1020-1025. PubMed ID: 35414301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-Avibactam Treatment for
    Marino A; Pulvirenti S; Campanella E; Stracquadanio S; Ceccarelli M; Micali C; Tina LG; Di Dio G; Stefani S; Cacopardo B; Nunnari G
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
    Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
    Gu J; Xu J; Zuo TT; Chen YB
    J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.
    Chen W; Sun L; Guo L; Cao B; Liu Y; Zhao L; Lu B; Li B; Chen J; Wang C
    Ann Transl Med; 2020 Feb; 8(3):39. PubMed ID: 32154284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
    Chen Y; Huang HB; Peng JM; Weng L; Du B
    Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
    Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of a Stable and Transferable
    Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
    Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
    Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
    J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant
    Varón-Vega FA; Lemos E; Castaño GN; Reyes JM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):235-240. PubMed ID: 34407710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review.
    Zhou Q; Wang H; Zhan T; Yang X; Wen L
    Infect Drug Resist; 2021; 14():1691-1701. PubMed ID: 33981150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.